COVID-19 Vaccines: With Narrowed Authorization For Janssen, US FDA Catches Up To CDC

Citing risk of thrombosis with thrombocytopenia syndrome, FDA restricts adenovirus-based vaccine to adults for whom other vaccines are not accessible or clinically appropriate, or who would not otherwise get a vaccine; action comes almost five months after CDC decided to preferentially favor the mRNA vaccines from Pfizer/BioNTech and Moderna.  

Two runners
FDA is catching up with CDC's recommendation on use of the Janssen COVID-19 vaccine. • Source: Shutterstock

Almost five months after the US Centers for Disease Control and Prevention decided to preferentially favor mRNA COVID-19 vaccines over Janssen Biotech Inc.’s adenovirus-based product, the Food and Drug Administration has followed suit, citing the latter’s risks of thrombosis with thrombocytopenia syndrome.

On 5 May, the FDA announced it was limiting authorization to individuals ≥18 years for whom other authorized or approved...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Vaccines

More from Pink Sheet